Meta-analyses of blood homocysteine levels for gender and genetic association studies of the MTHFR C677T polymorphism in schizophrenia

Schizophrenia Bulletin

Volumn 40, Issue 5, 2014, Pages 1154-1163

  Nishi, Akira ^a   Numata, Shusuke ^a   Tajima, Atsushi ^a   Kinoshita, Makoto ^a   Kikuchi, Kumiko ^a   Shimodera, Shinji ^b   Tomotake, Masahito ^a   Ohi, Kazutaka ^c   Hashimoto, Ryota ^c   Imoto, Issei ^a   Takeda, Masatoshi ^c   Ohmori, Tetsuro ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b KOCHI UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Japanese; Mendelian randomization; Plasma homocysteine; SNP

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CHLORPROMAZINE; HOMOCYSTEINE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN;

AMINO ACID BLOOD LEVEL; ARTICLE; CASE CONTROL STUDY; DSM-IV; GENETIC ASSOCIATION; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOCYSTEINE BLOOD LEVEL; HUMAN; INSTITUTIONAL ETHICS; MEDLINE; MENDELIAN RANDOMIZATION ANALYSIS; META ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; ADULT; AGED; BLOOD; COHORT ANALYSIS; FEMALE; GENETIC POLYMORPHISM; GENETICS; JAPAN; MALE; MIDDLE AGED; SEX DIFFERENCE;

ADULT; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HOMOCYSTEINE; HUMANS; JAPAN; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; SEX FACTORS;

EID: 84907348082     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbt154     Document Type: Article

References (88)

1. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2: e141.
2. Frankenburg FR. The role of one-carbon metabolism in schizophrenia and depression. Harv Rev Psychiatry. 2007;15: 146-160.
3. Krebs MO, Bellon A, Mainguy G, Jay TM, Frieling H. Onecarbon metabolism and schizophrenia: current challenges and future directions. Trends Mol Med. 2009;15: 562-570.
4. Regland B, Johansson BV, Grenfeldt B, Hjelmgren LT, Medhus M. Homocysteinemia is a common feature of schizophrenia. J Neural Transm Gen Sect. 1995;100: 165-169.
5. Levine J, Stahl Z, Sela BA, Gavendo S, Ruderman V, Belmaker RH. Elevated homocysteine levels in young male patients with schizophrenia. Am J Psychiatry. 2002;159: 1790-1792.
6. Applebaum J, Shimon H, Sela BA, Belmaker RH, Levine J. Homocysteine levels in newly admitted schizophrenic patients. J Psychiatr Res. 2004;38: 413-416.
7. Muntjewerff JW, Hoogendoorn ML, Kahn RS, et al. Hyperhomocysteinemia, methylenetetrahydrofolate reductase 677TT genotype, and the risk for schizophrenia: a Dutch population based case-control study. Am J Med Genet B Neuropsychiatr Genet. 2005;135B: 69-72.
8. Neeman G, Blanaru M, Bloch B, et al. Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am J Psychiatry. 2005;162: 1738-1740.
9. Lee YS, Han DH, Jeon CM, et al. Serum homocysteine, folate level and methylenetetrahydrofolate reductase 677, 1298 gene polymorphism in Korean schizophrenic patients. Neuroreport. 2006;17: 743-746.
10. Adler Nevo G, Meged S, Sela BA, Hanoch-Levi A, Hershko R, Weizman A. Homocysteine levels in adolescent schizophrenia patients. Eur Neuropsychopharmacol. 2006;16: 588-591.
11. Haidemenos A, Kontis D, Gazi A, Kallai E, Allin M, Lucia B. Plasma homocysteine, folate and B12 in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31: 1289-1296.
12. Akanji AO, Ohaeri JU, Al-Shammri SA, Fatania HR. Associations of blood homocysteine concentrations in Arab schizophrenic patients. Clin Biochem. 2007;40: 1026-1031.
13. Bromberg A, Levine J, Nemetz B, Belmaker RH, Agam G. No association between global leukocyte DNA methylation and homocysteine levels in schizophrenia patients. Schizophr Res. 2008;101: 50-57.
14. Petronijevic ND, Radonjic NV, Ivkovic MD, et al. Plasma homocysteine levels in young male patients in the exacerbation and remission phase of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32: 1921-1926.
15. Dietrich-Muszalska A, Olas B, Glowacki R, Bald E. Oxidative/nitrative modifications of plasma proteins and thiols from patients with schizophrenia. Neuropsychobiology. 2009;59: 1-7.
16. Feng LG, Song ZW, Xin F, Hu J. Association of plasma homocysteine and methylenetetrahydrofolate reductase C677T gene variant with schizophrenia: A Chinese Han populationbased case-control study. Psychiatry Res. 2009;168: 205-208.
17. Ma YY, Shek CC, Wong MC, et al. Homocysteine level in schizophrenia patients. Aust N Z J Psychiatry. 2009;43: 760-765.
18. García-Miss Mdel R, Pérez-Mutul J, López-Canul B, et al. Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa levels, but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia. J Psychiatr Res. 2010;44: 441-446.
19. Kale A, Naphade N, Sapkale S, et al. Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: implications for altered one-carbon metabolism. Psychiatry Res. 2010;175: 47-53.
20. Shlafman N, Shaldubin S, Applebaum J, Belmaker RH, Levine J. No gross abnormality of plasma homocysteine after acute methionine loading in clinically stabilized patients with schizophrenia. Asian J Psychiatr. 2010;3: 64-66.
21. Eren E, Yegin A, Yilmaz N, Herken H. Serum total homocystein, folate and vitamin B12 levels and their correlation with antipsychotic drug doses in adult male patients with chronic schizophrenia. Clin Lab. 2010;56: 513-518.
22. Kim TH, Moon SW. Serum homocysteine and folate levels in korean schizophrenic patients. Psychiatry Investig. 2011;8: 134-140.
23. Dietrich-Muszalska A, Malinowska J, Olas B, et al. The oxidative stress may be induced by the elevated homocysteine in schizophrenic patients. Neurochem Res. 2012;37: 1057-1062.
24. Kevere L, Purvina S, Bauze D, et al. Elevated serum levels of homocysteine as an early prognostic factor of psychiatric disorders in children and adolescents. Schizophr Res Treatment. 2012;2012: 373261.
25. Virgos C, Martorell L, Simó JM, et al. Plasma homocysteine and the methylenetetrahydrofolate reductase C677T gene variant: lack of association with schizophrenia. Neuroreport. 1999;10: 2035-2038.
26. Muntjewerff JW, van der Put N, Eskes T, et al. Homocysteine metabolism and B-vitamins in schizophrenic patients: low plasma folate as a possible independent risk factor for schizophrenia. Psychiatry Res. 2003;121: 1-9.
27. Goff DC, Bottiglieri T, Arning E, et al. Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry. 2004;161: 1705-1708.
28. Vilella E, Virgos C, Murphy M, et al. Further evidence that hyperhomocysteinemia and methylenetetrahydrofolate reductase C677T and A1289C polymorphisms are not risk factors for schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29: 1169-1174.
29. Ozcan O, Ipçioglu OM, Gültepe M, Basogglu C. Altered red cell membrane compositions related to functional vitamin B(12) deficiency manifested by elevated urine methylmalonic acid concentrations in patients with schizophrenia. Ann Clin Biochem. 2008;45: 44-49.
30. Bouaziz N, Ayedi I, Sidhom O, et al. Plasma homocysteine in schizophrenia: determinants and clinical correlations in Tunisian patients free from antipsychotics. Psychiatry Res. 2010;179: 24-29.
31. Gysin R, Kraftsik R, Boulat O, et al. Genetic dysregulation of glutathione synthesis predicts alteration of plasma thiol redox status in schizophrenia. Antioxid Redox Signal. 2011;15: 2003-2010.
32. Muntjewerff JW, Kahn RS, Blom HJ, den Heijer M. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry. 2006;11: 143-149.
33. Nygård O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA. 1995;274: 1526-1533.
34. Paré G, Chasman DI, Parker AN, et al. Novel associations of CPS1, MUT, NOX4, and DPEP1 with plasma homocysteine in a healthy population: a genome-wide evaluation of 13 974 participants in the Women's Genome Health Study. Circ Cardiovasc Genet. 2009;2: 142-150. doi: 10.1161/ CIRCGENETICS.108.829804.
35. Hazra A, Kraft P, Lazarus R, et al. Genome-wide significant predictors of metabolites in the one-carbon metabolism pathway. Hum Mol Genet. 2009;18: 4677-4687.
36. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10: 111-113.
37. Arinami T, Yamada N, Yamakawa-Kobayashi K, Hamaguchi H, Toru M. Methylenetetrahydrofolate reductase variant and schizophrenia/depression. Am J Med Genet. 1997;74: 526-528.
38. Kunugi H, Fukuda R, Hattori M, et al. C677T polymorphism in methylenetetrahydrofolate reductase gene and psychoses. Mol Psychiatry. 1998;3: 435-437.
39. Yoshimi A, Aleksic B, Kawamura Y, et al. Gene-wide association study between the methylenetetrahydrofolate reductase gene (MTHFR) and schizophrenia in the Japanese population, with an updated meta-analysis on currently available data. Schizophr Res. 2010;124: 216-222.
40. Tsutsumi A, Glatt SJ, Kanazawa T, et al. The genetic validation of heterogeneity in schizophrenia. Behav Brain Funct. 2011;7: 43.
41. Allen NC, Bagade S, McQueen MB, et al. Systematic metaanalyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet. 2008;40: 827-834.
42. Gilbody S, Lewis S, Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. Am J Epidemiol. 2007;165: 1-13.
43. Jönsson EG, Larsson K, Vares M, et al. Two methylenetetrahydrofolate reductase gene (MTHFR) polymorphisms, schizophrenia and bipolar disorder: an association study. Am J Med Genet B Neuropsychiatr Genet. 2008;147B: 976-982.
44. Lewis SJ, Zammit S, Gunnell D, Smith GD. A meta-analysis of the MTHFR C677T polymorphism and schizophrenia risk. Am J Med Genet B Neuropsychiatr Genet. 2005;135B: 2-4.
45. Peerbooms OL, van Os J, Drukker M, et al.; MTHFR in Psychiatry Group. Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: evidence for a common genetic vulnerability? Brain Behav Immun. 2011;25: 1530-1543.
46. Shi J, Gershon ES, Liu C. Genetic associations with schizophrenia: meta-analyses of 12 candidate genes. Schizophr Res. 2008;104: 96-107.
47. Zintzaras E. C677T and A1298C methylenetetrahydrofolate reductase gene polymorphisms in schizophrenia, bipolar disorder and depression: a meta-analysis of genetic association studies. Psychiatr Genet. 2006;16: 105-115.
48. Davey Smith G, Ebrahim S. What can mendelian randomisation tell us about modifiable behavioural and environmental exposures? BMJ. 2005;330: 1076-1079.
49. Burgess S, Butterworth A, Malarstig A, Thompson SG. Use of Mendelian randomisation to assess potential benefit of clinical intervention. BMJ. 2012;345: e7325.
50. Kinoshita M, Numata S, Tajima A, et al. Meta-analysis of association studies between DISC1 missense variants and schizophrenia in the Japanese population. Schizophr Res. 2012;141: 271-273.
51. Hashimoto R, Ohi K, Yasuda Y, et al. No association between the PCM1 gene and schizophrenia: a multi-center case-control study and a meta-analysis. Schizophr Res. 2011;129: 80-84.
52. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1987;422: 43-52.
53. Pichler I, Del Greco M F, Gögele M, et al.; PD GWAS Consortium; International Parkinson's Disease Genomics Consortium; Wellcome Trust Case Control Consortium 2; Genetics of Iron Status Consortium. Serum iron levels and the risk of Parkinson disease: a mendelian randomization study. PLoS Med. 2013;10: e1001462.
54. Bautista LE, Smeeth L, Hingorani AD, Casas JP. Estimation of bias in nongenetic observational studies using "mendelian triangulation". Ann Epidemiol. 2006;16: 675-680.
55. Thomas DC, Lawlor DA, Thompson JR. Re: Estimation of bias in nongenetic observational studies using "Mendelian triangulation" by Bautista et al. Ann Epidemiol. 2007;17: 511-513.
56. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315: 629-634.
57. Yue WH, Wang HF, Sun LD, et al. Genome-wide association study identifies a susceptibility locus for schizophrenia in Han Chinese at 11p11.2. Nat Genet. 2011;43: 1228-1231.
58. Stefansson H, Ophoff RA, Steinberg S, et al.; Genetic Risk and Outcome in Psychosis (GROUP). Common variants conferring risk of schizophrenia. Nature. 2009;460: 744-747.
59. Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium. Genome-wide association study identifies five new schizophrenia loci. Nat Genet. 2011;43: 969-976.
60. Brown AS, Bottiglieri T, Schaefer CA, et al. Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Arch Gen Psychiatry. 2007;64: 31-39.
61. Liu CC, Ho WY, Leu KL, Tsai HM, Yang TH. Effects of S- adenosylhomocysteine and homocysteine on DNA damage and cell cytotoxicity in murine hepatic and microglia cell lines. J Biochem Mol Toxicol. 2009;23: 349-356.
62. Kruman II, Culmsee C, Chan SL, et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci. 2000;20: 6920-6926.
63. Tyagi N, Moshal KS, Ovechkin AV, et al. Mitochondrial mechanism of oxidative stress and systemic hypertension in hyperhomocysteinemia. J Cell Biochem. 2005;96: 665-671.
64. Kinoshita M, Numata S, Tajima A, Shimodera S, Imoto I, Ohmori T. Plasma total homocysteine is associated with DNA methylation in patients with schizophrenia. Epigenetics. 2013;8: 584-590.
65. Kirkbride JB, Susser E, Kundakovic M, Kresovich JK, Davey Smith G, Relton CL. Prenatal nutrition, epigenetics and schizophrenia risk: can we test causal effects? Epigenomics. 2012;4: 303-315.
66. Levine J, Stahl Z, Sela BA, et al. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry. 2006;60: 265-269.
67. Hill M, Shannahan K, Jasinski S, et al. Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr Res. 2011;127: 41-45.
68. Roffman JL, Lamberti JS, Achtyes E, et al. Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry. 2013;70: 481-489.
69. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291: 565-575.
70. Spence JD, Bang H, Chambless LE, Stampfer MJ. Vitamin Intervention For Stroke Prevention trial: an efficacy analysis. Stroke. 2005;36: 2404-2409.
71. Martí-Carvajal AJ, Solà I, Lathyris D, Karakitsiou DE, Simancas-Racines D. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2013;1: CD006612.
72. Dong ZQ, Tian YY, Guan X, et al. Genetic polymorphism of methylenetetrahydrofolate reductase and risk of aggressive behaviour in schizophrenia. Psychiatry Res. 2012;200: 1082.
73. Kontis D, Theochari E, Fryssira H, et al. COMT and MTHFR polymorphisms interaction on cognition in schizophrenia: an exploratory study. Neurosci Lett. 2013;537: 17-22.
74. Roffman JL, Weiss AP, Deckersbach T, et al. Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia. Schizophr Res. 2007;92: 181-188.
75. Roffman JL, Gollub RL, Calhoun VD, et al. MTHFR 677C rarr; T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val rarr; Met. Proc Natl Acad Sci U S A. 2008;105: 17573-17578.
76. Roffman JL, Weiss AP, Purcell S, et al. Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol Psychiatry. 2008;63: 42-48.
77. Roffman JL, Brohawn DG, Friedman JS, et al. MTHFR 677C>T effects on anterior cingulate structure and function during response monitoring in schizophrenia: a preliminary study. Brain Imaging Behav. 2011;5: 65-75.
78. Roffman JL, Nitenson AZ, Agam Y, et al. A hypomethylating variant of MTHFR, 677C>T, blunts the neural response to errors in patients with schizophrenia and healthy individuals. PLoS One. 2011;6: e25253.
79. Roffman JL, Brohawn DG, Nitenson AZ, Macklin EA, Smoller JW, Goff DC. Genetic variation throughout the folate metabolic pathway influences negative symptom severity in schizophrenia. Schizophr Bull. 2013;39: 330-338.
80. Zhang Y, Yan H, Tian L, et al. Association of MTHFR C677T polymorphism with schizophrenia and its effect on episodic memory and gray matter density in patients. Behav Brain Res. 2013;243: 146-152.
81. Ellingrod VL, Miller DD, Taylor SF, Moline J, Holman T, Kerr J. Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr Res. 2008;98: 47-54.
82. Ellingrod VL, Taylor SF, Dalack G, et al. Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics. J Clin Psychopharmacol. 2012;32: 261-265.
83. Vehof J, Burger H, Wilffert B, Al Hadithy A, Alizadeh BZ, Snieder H; GROUP investigators. Clinical response to antipsychotic drug treatment: association study of polymorphisms in six candidate genes. Eur Neuropsychopharmacol. 2012;22: 625-631.
84. Joober R, Benkelfat C, Lal S, et al. Association between the methylenetetrahydrofolate reductase 677Crarr;T missense mutation and schizophrenia. Mol Psychiatry. 2000;5: 323-326.
85. Schwartz S, Susser E. The use of well controls: an unhealthy practice in psychiatric research. Psychol Med. 2011;41: 1127-1131.
86. Bochud M. On the use of Mendelian randomization to infer causality in observational epidemiology. Eur Heart J. 2008;29: 2456-2457.
87. Almeida OP, McCaul K, Hankey GJ, Normand P, Jamrozik K, Flicker L. Homocysteine and depression in later life. Arch Gen Psychiatry. 2008;65: 1286-1294.
88. Wald DS, Kasturiratne A, Simmonds M. Serum homocysteine and dementia: meta-analysis of eight cohort studies including 8669 participants. Alzheimers Dement. 2011;7: 412-417.